Preclinical evaluation of lovastatin.
Administration of lovastatin to animals at high dosage levels produces a broad spectrum of toxicity. This toxicity is expected based on the critical nature of the target enzyme (HMG CoA reductase) and the magnitude of the dosage levels used. The information reviewed in this paper demonstrates that these adverse findings in animals do not predict significant risk in humans. The reason for this derives from the fact that all the available evidence suggests that the adverse effects observed are produced by an exaggeration of the desired biochemical effect of the drug at high dosage levels. The presence of clear and high no-effect doses for these toxic effects along with the fact that most of the changes observed are clearly mechanism-based (directly attributable to inhibition of mevalonate synthesis) indicate that it is unlikely that similar changes will be observed at the therapeutic dosage levels in humans. This hypothesis is supported by the extensive human safety experience described by Tobert in the following report.
MacDonald
J S
JS
Department of Safety Assessment, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Gerson
R J
RJ
Kornbrust
D J
DJ
Kloss
M W
MW
Prahalada
S
S
Berry
P H
PH
Alberts
A W
AW
Bokelman
D L
DL
D000818:Animals; D002386:Cataract / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008099:Liver / Q000187:drug effects; D008148:Lovastatin / Q000008:administration & dosage / Q000633:toxicity*; D009374:Neoplasms, Experimental / Q000139:chemically induced; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin